664 related articles for article (PubMed ID: 21484570)
1. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy.
Wang M
Handb Exp Pharmacol; 2011; (203):127-46. PubMed ID: 21484570
[TBL] [Abstract][Full Text] [Related]
2. Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11beta-hydroxysteroid dehydrogenase type 1) gene.
Iwasaki Y; Takayasu S; Nishiyama M; Tsugita M; Taguchi T; Asai M; Yoshida M; Kambayashi M; Hashimoto K
Mol Cell Endocrinol; 2008 Mar; 285(1-2):10-8. PubMed ID: 18313835
[TBL] [Abstract][Full Text] [Related]
3. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
Stimson RH; Walker BR
Minerva Endocrinol; 2007 Sep; 32(3):141-59. PubMed ID: 17912154
[TBL] [Abstract][Full Text] [Related]
4. 11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
Tomlinson JW
Minerva Endocrinol; 2005 Mar; 30(1):37-46. PubMed ID: 15877012
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in the discovery of 11beta-HSD1 inhibitors.
Boyle CD
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):495-511. PubMed ID: 18600567
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target.
Wamil M; Seckl JR
Drug Discov Today; 2007 Jul; 12(13-14):504-20. PubMed ID: 17631244
[TBL] [Abstract][Full Text] [Related]
7. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
Anagnostis P; Katsiki N; Adamidou F; Athyros VG; Karagiannis A; Kita M; Mikhailidis DP
Metabolism; 2013 Jan; 62(1):21-33. PubMed ID: 22652056
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of 11β-hydroxysteroid dehydrogenase 1 by carbenoxolone affects glucose homeostasis and obesity in db/db mice.
Dhanesha N; Joharapurkar A; Shah G; Kshirsagar S; Dhote V; Sharma A; Jain M
Clin Exp Pharmacol Physiol; 2012 Jan; 39(1):69-77. PubMed ID: 22060140
[TBL] [Abstract][Full Text] [Related]
9. Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor in the diet-induced obese mice.
Park JS; Rhee SD; Jung WH; Kang NS; Kim HY; Kang SK; Ahn JH; Kim KY
Eur J Pharmacol; 2012 Sep; 691(1-3):19-27. PubMed ID: 22760069
[TBL] [Abstract][Full Text] [Related]
10. 11beta-hydroxysteroid dehydrogenase type 1 as a modulator of glucocorticoid action: from metabolism to memory.
Seckl JR; Walker BR
Trends Endocrinol Metab; 2004 Nov; 15(9):418-24. PubMed ID: 15519888
[TBL] [Abstract][Full Text] [Related]
11. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome.
Schnackenberg CG
Curr Opin Investig Drugs; 2008 Mar; 9(3):295-300. PubMed ID: 18311666
[TBL] [Abstract][Full Text] [Related]
12. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents.
Boyle CD; Kowalski TJ
Expert Opin Ther Pat; 2009 Jun; 19(6):801-25. PubMed ID: 19456274
[TBL] [Abstract][Full Text] [Related]
13. 11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus.
Pereira CD; Azevedo I; Monteiro R; Martins MJ
Diabetes Obes Metab; 2012 Oct; 14(10):869-81. PubMed ID: 22321826
[TBL] [Abstract][Full Text] [Related]
14. Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis.
Lloyd DJ; Helmering J; Cordover D; Bowsman M; Chen M; Hale C; Fordstrom P; Zhou M; Wang M; Kaufman SA; Véniant MM
Diabetes Obes Metab; 2009 Jul; 11(7):688-99. PubMed ID: 19527482
[TBL] [Abstract][Full Text] [Related]
15. 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
Morton NM; Seckl JR
Front Horm Res; 2008; 36():146-164. PubMed ID: 18230901
[TBL] [Abstract][Full Text] [Related]
16. In vivo activity of 11β-hydroxysteroid dehydrogenase type 1 in man: effects of prednisolone and chenodesoxycholic acid.
Diederich S; Quinkler M; Mai K; Schöneshöfer M; Baehr V; Pfeiffer A; Oelkers W; Eigendorff E
Horm Metab Res; 2011 Jan; 43(1):66-71. PubMed ID: 20925019
[TBL] [Abstract][Full Text] [Related]
17. Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects.
Alberti L; Girola A; Gilardini L; Conti A; Cattaldo S; Micheletto G; Invitti C
Int J Obes (Lond); 2007 Dec; 31(12):1826-31. PubMed ID: 17593901
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for the treatment of metabolic syndrome.
Wang M
Curr Opin Investig Drugs; 2006 Apr; 7(4):319-23. PubMed ID: 16625818
[TBL] [Abstract][Full Text] [Related]
19. Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.
Masuzaki H; Flier JS
Curr Drug Targets Immune Endocr Metabol Disord; 2003 Dec; 3(4):255-62. PubMed ID: 14683456
[TBL] [Abstract][Full Text] [Related]
20. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development.
Ge R; Huang Y; Liang G; Li X
Curr Med Chem; 2010; 17(5):412-22. PubMed ID: 20015040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]